How Robots Are Introducing A New Dimension To Healthcare Service Delivery

Pharmaceutical

Incyte’s Clinical Trial for Myelofibrosis; Eisa...

Incyte Halts Phase III Clinical Trial for Myelofibrosis  Incyte announced the termination of Phase III LIMBER-304 trial after the results of a pre-planned interim analysis conducted by an inde...

Mar 07, 2023

acute-ischemic-stroke-treatment-outlook
Wider Administration Window – Need of the Moment for Acute Ischemic Stroke Patients

Acute ischemic stroke, contributing up to 80% of all stroke cases, is among the leading causes of death and morbidity, leaving around 50% of stroke survivors disabled worldwide. It is caused due to the blockage of an artery resulting in reduced blood flow to the brain that damages and interrupts brain functions. Hi...

Find More
besremi-jakafi-rusfertide-for-polycythemia-vera-treatment
Polycythemia Vera Treatment: Besremi, Jakafi, and Rusfertide Analysis

There is a wider opportunity for BESREMi; Jakafi is not a direct competitor to Besremi, and there is uncertainty around Rusfertide’s uptake. BESREMi is expanding its horizon in the first-line treatment of Polycythemia vera; JAKAFI’s impressive growth in second-line treatment The polycythemia vera treatment par...

Find More
Pharma News and Updates for SpringWorks Therapeutics, AskBio, Mitsubishi Tanabe Pharma America, Sage Therapeutics, Biohaven Pharma
SpringWorks’s Desmoid Tumors Therapeutic, Nirogacestat; Orphan Drug Designation to AskBio’s AB-1003; Mitsubishi Tanabe’s Phase 3 Trial of RADICAVA ORS in ALS; EU Orphan Drug Designation to Sage Therapeutics’s SAGE-718; FDA Fast Track Status to Biohaven’s Taldefgrobep Alfa

Sage Therapeutics Receives EU Orphan Drug Designation for Huntington's Disease Treatment Candidate Sage Therapeutics declared the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is developing as a potential oral therapy for cognitive disor...

Find More

More Views & Analysis

minimal-residue-disease-mrd-testing-market
Minimal Residual Disease (MRD) Testing: A Path to Cure Cancer?

Measurable or Minimal Residual Disease (MRD) is a term often used when treating patients with blood cancers. MRD is a small number of cancer cells left in the body after cancer treatment, and these cells can potentially cause relapse in these patients. The number of remaining cells is often too small to cause any s...

Find More

ASCO GU 2023, Prostate & Urothelial Cancer Abstracts Highlights
A Quick Recap from ASCO GU 2023: Prostate and Urothelial Cancer Highlights

The ASCO Genitourinary (GU) Cancers Symposium, which ended on February 18, 2023, was a three-day scientific and educational meeting designed to provide attendees with in-depth, multidisciplinary analysis of the timely topics in the study, diagnosis, and treatment of GU malignancies. DelveInsight has compiled the sy...

Find More

top-10-oncology-drugs-launches-2023
Top 10 Expected Oncology Drug Launches in 2023

Cancer is the world’s second leading cause of death. Every year, 10 million people die from cancer. Cancer kills 70% of people in low-to-middle-income countries. Cancer is estimated to cost the global economy USD 1.16 trillion per year. Millions of lives could be saved annually by implementing resource-appropriate ...

Find More

Protein Supplements Market, Growing Demand, and Key Companies
How is Protein Supplements Market Evolving with the Ongoing Development?

Protein supplements are critical in building and repairing muscles and maintaining their growth. People from specific groups, such as athletes and fitness enthusiasts, rely heavily on essential nutrients to build muscle and recover faster after intense workouts. Moreover, protein supplements are also beneficial for...

Find More

donanemab-for-alzheimers-disease-treatment
The Road Ahead for Donanemab: Will the Therapy be the Next Imminent Breakthrough in the Alzheimer’s Disease Treatment Landscape?

Alzheimer’s disease (AD) is becoming a rapidly growing public health concern due to the rise in the world’s aging population. Based on the data obtained from the 2019 Global Burden of Disease (GBD) database, the incidence and prevalence of Alzheimer’s disease and other dementias increased by 147.95 and 160.84%, res...

Find More

epstein-barr-virus-ebv-treatment-outlook
Changing Landscape of EBV-associated Diseases Treatment: Is T-cell Immunotherapy the Answer?

Epstein–Barr virus (EBV), also known as human herpesvirus 4 (HHV-4), was discovered in the 1960s as an inescapable virus that infects almost 95% of the world’s population and causes nearly 1% of all cancers. Besides, the virus is a leading cause of infectious mononucleosis (IM) and is associated with different subt...

Find More

Dry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....

Find More

West Nile Disease is a disease caused by the West Nile Virus, a flavivirus associated with the virus.....

Find More

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD.....

Find More

It was assumed initially that Alzheimer’s Disease was a rare condition, but now it is considered t.....

Find More

Scleroderma is a chronic disease that affects the skin, the connective tissue that supports and hold.....

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More